查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1553622

卵巢症候群治疗市场规模、份额和趋势分析报告：按药物类别、手术、分销管道、地区和细分市场预测，2024-2030年

Polycystic Ovarian Syndrome Treatment Market Size, Share & Trends Analysis Report By Drug Class (Oral Contraceptives, Antiandrogens), By Surgery, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格
简介目录

多囊性卵巢治疗市场的成长与趋势：

Grand View Research, Inc.最新报告显示，到2030年，全球卵巢囊性卵巢症候群治疗市场规模将达到69.9亿美元，2024年至2030年复合年增长率为6.5%。

根据美国疾病管制与预防中心 (CDC) 的数据，美国卵巢(PCOS) 是女性不孕症的最常见原因。在美国，大约 6% 至 12% 的育龄女性患有 PCOS。此外，随着病情的进展，会出现代谢异常，如果延迟治疗，可能会发展为第2型糖尿病。此疾病的严重程度会增加患者罹患子宫内膜癌的风险。因此，早期诊断和有效治疗对于復健非常重要。

目前，市面上还没有针对这种疾病的特效药物。因此，治疗症状是治疗方法的首要目标。由于与此综合征相关的症状多种多样，因此使用不同的药物类别/组合进行治疗。因此，新兴市场领导者专注于开拓特定药物/治疗方法来治疗这种疾病的根本原因。Astra Zeneca是参与开发此类药物的领导者之一。

多囊性卵巢治疗市场报告亮点

  • 多囊性卵巢症候群盛行率的持续上升主要推动了全球该市场的成长。
  • 政府机构和市场相关人员正在努力提高女性对多囊性卵巢症候群早期诊断的好处和现有治疗方法的认识，从而推动了市场的发展。
  • 多囊性卵巢症候群的治疗主要包括生活方式的改变，如均衡饮食和锻炼，以及口服避孕药、抗雄激素、胰岛素增敏剂、抗肥胖药物和抗忧郁症等药物治疗。
  • 如果药物治疗对病情没有反应，则首选手术治疗，例如卵巢楔形切除术或腹腔镜卵巢打孔术。
  • 胰岛素增敏剂在市场上占据主导地位，因为它们被广泛用于治疗胰岛素抗性以预防糖尿病（一种与多囊性卵巢症候群相关的风险）。
  • 口服避孕药（OCP）领域预计将以最快的速度成长，其次是用于治疗多毛症和痤疮等症状性疾病的抗雄激素药物。
  • 北美占据市场主导地位，其次是欧洲。该地区的高市场份额得益于其高知名度和先进的医疗设施。
  • 政府加强提高人们对多囊性卵巢症候群症状、诊断和可用治疗方法的认识，导致该地区被诊断出患有此症候群的女性人数不断增加。
  • 中国是利润最丰厚的市场之一，由于中国有大量患有多囊性卵巢症候群的肥胖女性，因此为全球和本土公司提供了巨大的成长机会。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章多囊性卵巢治疗市场变数、趋势与范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 多囊性卵巢治疗市场分析工具
    • 波特的分析
    • PESTEL分析

第四章多囊性卵巢治疗市场：依药物类别估算与趋势分析

  • 细分仪表板
  • 多囊性卵巢治疗市场：2023 年和 2030 年按药物类别的变化分析
  • 口服避孕药
  • 抗雄激素
  • 胰岛素增敏剂
  • 抗忧郁症
  • 预防肥胖

第五章多囊性卵巢卵巢治疗市场：手术估计与趋势分析

  • 细分仪表板
  • 多囊性卵巢治疗市场：2023 年和 2030 年手术变化分析
  • 卵巢楔形切除术
  • 腹腔镜卵巢穿孔

第六章多囊性卵巢治疗市场：按分销管道估计和趋势分析

  • 细分仪表板
  • 多囊性卵巢治疗市场：2023 年和 2030 年分销管道变化分析
  • 医院药房
  • 药局和零售药局
  • 线上提供者

第七章多囊性卵巢卵巢治疗市场：区域估计与趋势分析

  • 2023 年及 2030 年多卵巢治疗市场占有率（按地区）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
  • 拉丁美洲
    • 巴西
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • AstraZeneca
    • Bayer AG
    • Merck KGaA.
    • Abbott
    • Pfizer, Inc
    • Sanofi
    • Bristol Myers Squibb Company
    • Teva Pharmaceutical Industries Ltd
    • Novartis AG
    • Ferring BV
简介目录
Product Code: GVR-2-68038-203-7

Polycystic Ovarian Syndrome Treatment Market Growth & Trends:

The global polycystic ovarian syndrome treatment market size is expected to reach USD 6.99 billion by 2030, registering a CAGR of 6.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. According to the Centers of Disease Control & Prevention (CDC), Polycystic Ovary Syndrome (PCOS) is the most common cause of female infertility. Approximately 6% to 12% women of reproductive age suffer from PCOS in the U. S. Moreover, progression of this condition can lead to metabolic abnormalities, which may result in development of type 2 diabetes, if the syndrome is not treated on time. The severity of the disorder increases the risk of developing uterine and endometrial cancers in patients. Thus, early diagnosis and effective treatment are significant for successful recovery.

Presently, no specific drug is commercially available for this condition. Thus, treating symptoms is the prime aim of the treatment regimen. Owing to the various symptoms associated with this syndrome, a range of drug class/combinations is used in the treatment. Therefore, market leaders are focusing on developing a specific drug/treatment to cure the root cause of this disease. AstraZeneca is one of the leaders involved in developing such a drug.

Polycystic Ovarian Syndrome Treatment Market Report Highlights:

  • Constantly rising prevalence of PCOS is primarily driving the growth of this market across the globe
  • Initiatives undertaken by government bodies and market players to create awareness about benefits of early diagnosis and commercially available treatment for PCOS among women is boosting the market
  • Treatment of PCOS mainly includes lifestyle modification through balanced diet, exercise, and drugs such as oral contraceptives, antiandrogens, insulin-sensitizing agents, anti-obesity agents, and antidepressants
  • Surgical procedures such as ovarian wedge resection and laparoscopic ovarian drilling are preferred when patients do not respond to drug therapy
  • Insulin-sensitizing agents segment is dominating the market since these drugs are widely used for treatment of insulin resistance to prevent diabetes, which is a risk associated with PCOS
  • Oral Contraceptive Pills (OCPs) segment is expected to grow at the fastest rate followed by antiandrogen agents that are used for treating symptomatic conditions such as hirsutism and acne
  • North America is dominating the market followed by Europe. High awareness and availability of advanced healthcare facilities are factors responsible for the dominant share held by this region
  • Asia Pacific is expected to be the fastest growing region over the forecast period.Increasing government initiatives for raising awareness about symptoms & diagnosis of PCOS and available treatment are increasing the number of women being diagnosed with this syndrome in the region
  • China is one of the most lucrative markets with tremendous growth opportunities for global as well as local players owing to presence of a large pool of obese female population, which is at high risk of PCOS

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Polycystic Ovarian Syndrome Treatment Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Billion)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Polycystic Ovarian Syndrome Treatment Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Polycystic Ovarian Syndrome Treatment Market: Drug Class Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Polycystic Ovarian Syndrome Treatment Market: Drug Class Movement Analysis, 2023 & 2030 (USD Billion)
  • 4.3. Oral Contraceptives
    • 4.3.1. Oral Contraceptives Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.4. Antiandrogens
    • 4.4.1. Antiandrogens Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.5. Insulin-sensitizing Agent
    • 4.5.1. Insulin-sensitizing Agent Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.6. Antidepressant
    • 4.6.1. Antidepressant Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.7. Anti-obesity
    • 4.7.1. Anti-obesity Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. Polycystic Ovarian Syndrome Treatment Market: Surgery Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Polycystic Ovarian Syndrome Treatment Market: Surgery Movement Analysis, 2023 & 2030 (USD Billion)
  • 5.3. Ovarian Wedge Resection
    • 5.3.1. Ovarian Wedge Resection Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.4. Laparoscopic Ovarian Drilling
    • 5.4.1. Laparoscopic Ovarian Drilling Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Polycystic Ovarian Syndrome Treatment Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Polycystic Ovarian Syndrome Treatment Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Billion)
  • 6.3. Hospital Pharmacy
    • 6.3.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.4. Drug Store & Retail Pharmacy
    • 6.4.1. Drug Store & Retail Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.5. Online Providers
    • 6.5.1. Online Providers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. Polycystic Ovarian Syndrome Treatment Market: Regional Estimates & Trend Analysis

  • 7.1. Polycystic Ovarian Syndrome Treatment Market Share, By Region, 2023 & 2030 (USD Billion)
  • 7.2. North America
    • 7.2.1. North America Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.2.2. U.S.
    • 7.2.3. U.S. Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.2.4. Canada
      • 7.2.4.1. Canada Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.2.5. Mexico
      • 7.2.5.1. Mexico Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.3. Europe
    • 7.3.1. Europe Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.2. UK
      • 7.3.2.1. UK Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.4. France
      • 7.3.4.1. France Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.2. China
      • 7.4.2.1. China Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.4. India
      • 7.4.4.1. India Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5. Latin America
    • 7.5.1. Latin America Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.3. UAE
      • 7.6.3.1. UAE Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.4. South Africa
      • 7.6.4.1. South Africa Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. AstraZeneca
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Bayer AG
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Merck KGaA.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Abbott
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Pfizer, Inc
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Sanofi
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Bristol Myers Squibb Company
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Teva Pharmaceutical Industries Ltd
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Novartis AG
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Ferring B.V.
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives